Accueil 
Nota Bene Cancer V2 Numéro 136 du 15 Mai 2012 Traitements Fiche de publication
Acute Myeloid Leukemia and Myelodysplastic Syndromes After Radiation Therapy Are Similar to De Novo Disease and Differ From Other Therapy-Related Myeloid Neoplasms
Menée sur 450 patients, cette étude montre qu'une leucémie myéloïde aiguë (LMA) et un syndrome myélodysplasique (SM) survenus après une radiothérapie sont semblables aux LMA et SM sporadiques mais diffèrent des LMA et SM consécutifs à une chimiothérapie ou à des traitements combinés
- Journal of Clinical Oncology, sous presse, 2012 (résumé)
Résumé en anglais :
Purpose Therapy-related myeloid neoplasms (t-MN) represent a unique clinical syndrome occurring in patients treated with chemotherapy and/or external-beam radiation (XRT) and are characterized by poorer prognosis compared with de novo disease. XRT techniques have evolved in recent years and are associated with significantly reduced bone marrow exposure. The characteristics of post-XRT t-MN in the current era have not been studied.Patients and Methods We analyzed patients who developed acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) after XRT alone (47 patients) or cytotoxic chemotherapy/combined-modality therapy (C/CMT, 181 patients) and compared them with patients with de novo MDS or AML (222 patients). We estimated bone marrow exposure to radiation and compared the clinical, pathologic, and cytogenetic features and outcome of the XRT patients with the C/CMT patients and with patients with de novo MDS and AML.Results Patients with t-MN after XRT alone had superior overall survival (P = .006) and lower incidence of high-risk karyotypes (P = .01 for AML and < .001 for MDS) compared with patients in the C/CMT group. In contrast, there were no significant differences in survival or frequency of high-risk karyotypes between the XRT and de novo groups.Conclusion AML and MDS diagnosed in the past decade in patients after receiving XRT alone differ from t-MN occurring after C/CMT and share genetic features and clinical behavior with de novo AML/MDS. Our results suggest that post-XRT MDS/AML may not represent a direct consequence of radiation toxicity and warrant a therapeutic approach similar to de novo disease.
Mots clés : Leucémie; Traitements (Combinaison de traitements localisés et systémiques)
Recherche de publications
Widget
Archives
Formulaire d’abonnement
Pour recevoir gratuitement chaque nouveau numéro de Nota Bene Cancer par courriel :
Sources
Pour visualiser l'ensemble des sources alimentant le Nota Bene Cancer :
Foire aux questions
Pour trouver les réponses aux questions que vous vous posez sur Nota Bene Cancer :
